GBP14.85
7.61% today
London, Feb 05, 05:44 pm CET
ISIN
GB00BN7SWP63
Symbol
GSK
Sector
Industry

GlaxoSmithKline Target price 2025 - Analyst rating & recommendation

GlaxoSmithKline Classifications & Recommendation:

Buy
33%
Hold
50%
Sell
17%

GlaxoSmithKline Price Target

Target Price GBP16.11
Price GBP14.85
Potential
Number of Estimates 18
18 Analysts have issued a price target GlaxoSmithKline 2026 . The average GlaxoSmithKline target price is GBP16.11. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 24 analysts: 8 Analysts recommend GlaxoSmithKline to buy, 12 to hold and 4 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2026 of . Most analysts recommend the GlaxoSmithKline stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Billion GBP 30.33 31.11
3.42% 2.59%
EBITDA Margin 30.62% 33.31%
1.71% 8.78%
Net Margin 16.41% 12.11%
68.20% 26.22%

18 Analysts have issued a sales forecast GlaxoSmithKline 2024 . The average GlaxoSmithKline sales estimate is

GBP31.1b
Unlock
. This is
0.63% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
GBP31.6b 0.93%
Unlock
, the lowest is
GBP30.9b 1.42%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 GBP30.3b 3.42%
2024
GBP31.1b 2.59%
Unlock
2025
GBP32.4b 4.00%
Unlock
2026
GBP34.1b 5.53%
Unlock
2027
GBP35.7b 4.65%
Unlock
2028
GBP36.2b 1.33%
Unlock

14 Analysts have issued an GlaxoSmithKline EBITDA forecast 2024. The average GlaxoSmithKline EBITDA estimate is

GBP10.4b
Unlock
. This is
14.37% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
GBP12.0b 32.07%
Unlock
, the lowest is
GBP6.8b 24.72%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 GBP9.3b 5.19%
2024
GBP10.4b 11.60%
Unlock
2025
GBP11.2b 7.66%
Unlock
2026
GBP12.2b 9.22%
Unlock
2027
GBP12.9b 6.02%
Unlock
2028
GBP11.8b 8.50%
Unlock

EBITDA Margin

2023 30.62% 1.71%
2024
33.31% 8.78%
Unlock
2025
34.48% 3.51%
Unlock
2026
35.69% 3.51%
Unlock
2027
36.15% 1.29%
Unlock
2028
32.65% 9.68%
Unlock

11 GlaxoSmithKline Analysts have issued a net profit forecast 2024. The average GlaxoSmithKline net profit estimate is

GBP3.8b
Unlock
. This is
49.00% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
GBP6.4b 152.57%
Unlock
, the lowest is
GBP2.4b 5.81%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 GBP5.0b 67.12%
2024
GBP3.8b 24.28%
Unlock
2025
GBP6.1b 61.40%
Unlock
2026
GBP6.9b 12.84%
Unlock
2027
GBP7.5b 9.74%
Unlock
2028
GBP7.4b 1.37%
Unlock

Net Margin

2023 16.41% 68.20%
2024
12.11% 26.22%
Unlock
2025
18.80% 55.24%
Unlock
2026
20.10% 6.91%
Unlock
2027
21.08% 4.88%
Unlock
2028
20.52% 2.66%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share GBP 1.22 0.92
67.12% 24.59%
P/E 14.94
EV/Sales 2.20

11 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

GBP0.92
Unlock
. This is
48.39% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
GBP1.57 153.23%
Unlock
, the lowest is
GBP0.58 6.45%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 GBP1.22 67.12%
2024
GBP0.92 24.59%
Unlock
2025
GBP1.49 61.96%
Unlock
2026
GBP1.68 12.75%
Unlock
2027
GBP1.85 10.12%
Unlock
2028
GBP1.82 1.62%
Unlock

P/E ratio

Current 22.38 69.03%
2024
14.94 33.24%
Unlock
2025
9.26 38.02%
Unlock
2026
8.20 11.45%
Unlock
2027
7.47 8.90%
Unlock
2028
7.58 1.47%
Unlock

Based on analysts' sales estimates for 2024, the GlaxoSmithKline stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.19 14.45%
2024
2.20 0.68%
Unlock
2025
2.12 3.85%
Unlock
2026
2.01 5.25%
Unlock
2027
1.92 4.45%
Unlock
2028
1.89 1.31%
Unlock

P/S ratio

Current 1.80 16.55%
2024
1.81 0.63%
Unlock
2025
1.74 3.85%
Unlock
2026
1.65 5.24%
Unlock
2027
1.58 4.45%
Unlock
2028
1.56 1.31%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today